The Biotech Breakthrough that
is redefining how chronic wounds heal with the potential for VC-like investor returns
A $15 billion global market. One pharmaceutical therapy targeting four biological pathways, healing 3 times more wounds than standard treatments
Join our exclusive investor briefing to evaluate the opportunity.
October 29th, 2025 | 10:00 AM ET
Limited to Accredited Investors
Why This Matters to Investors
~230 diabetes related amputations occur daily in the U.S.
Yet therapeutic innovation has remained stagnant for decades.
The wound care market now exceeds $15 billion annually, but most
therapies treat symptoms, not biological root causes.
Our solution provides a pharmaceutical therapy where low-tech
solutions exist. It addresses four healing pathways simultaneously.
This represents a convergence of scientific validation and market
opportunity that sophisticated investors recognize.
Investment Thesis Highlights
Massive Addressable Market
Healthcare systems need cost effective solutions for tens of billions in annual wound
treatment expenses
Platform
Technology
Cell therapy architecture
with potential applications
across multiple indications
Clinical
Validation
Phase II blinded
study completed
Capital
Efficiency
Lean development strategy targeting key value inflection points before Series B
Briefing Agenda
45 Minutes of Substantive Content
Technology
Deep Dive
Mechanism of action, intellectual property portfolio, and competitive differentiation.
Clinical
Evidence
Clinical data demonstrating safety, efficacy, and patient benefit.
Market Entry
Strategy
Path to capturing share
in the chronic wound
care market.
Live Q&A
Session
Direct access to
management team for
detailed questioning.
Meet the Speakers
Alberto Piaggesi
David G. Armstrong
Scientific Advisory Board Member
Director of the Diabetic Foot Unit,
University Hospital of Pisa.
100+ peer-reviewed publications in
diabetic foot and wound care.
Scientific Advisory Board Member
Distinguished Professor of Surgery,
University of Southern California.
700+ peer-reviewed publications in wound
healing and limb salvage.
ABOUT US
Aurealis: Where Multi-Target Biology Meets Commercial Execution
Our 4-in-1 platform simultaneously addresses inflammation, angiogenesis, ECM remodeling, and cellular regeneration – overcoming the limitations of single-target approaches that have dominated chronic wound care for decades.
Discover how our technology is re-defining the treatment of chronic wounds (diabetic foot ulcers, venous leg ulcers), cancers (ovarian, peritoneal, bladder, recurrent melanoma), and beyond.
